1810055G02Rik Activators
The activators of 1810055G02Rik function through a variety of biochemical mechanisms, each contributing to the enhancement of the protein's activity. Compounds such as Forskolin and IBMX increase intracellular cAMP levels, subsequently activating PKA, which may phosphorylate and thus enhance the activity of 1810055G02Rik if it is part of the cAMP signaling pathway. The direct activation of PKC by PMA could also result in the phosphorylation of 1810055G02Rik, assuming it is a substrate or part of a PKC-regulated signaling cascade. 1810055G02Rik Activators are a category of chemicals that target and activate the 1810055G02Rik gene, a gene implicated in various cellular pathways within the mouse genome. The discovery of these activators typically begins with large-scale screenings, which assess the ability of numerous compounds to modulate gene expression. In such screenings, a reporter assay system is integral, where the promoter of the 1810055G02Rik gene is linked to a reporter such as luciferase.
This enzyme, upon expression, catalyzes a reaction that emits light, which is then quantified. The compounds that facilitate an upsurge in luminescence indicate a successful activation of the gene's promoter. These compounds are then earmarked for further validation as activators. Upon isolating these candidate activators, further validation employs a set of sophisticated techniques. One such technique is quantitative PCR (qPCR), which measures the abundance of mRNA transcripts of the 1810055G02Rik gene following interaction with these compounds. A significant increase in mRNA levels, as determined by qPCR, suggests that the gene's transcription is being activated by the compounds in question. To complement the findings from qPCR, Western blot analysis is conducted to examine whether the elevated mRNA levels are reflected at the protein level. Western blotting can provide information about the protein's expression, stability, and any modifications that result from activator interaction.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP and cGMP levels in the cell. This can enhance PKA and PKG activity, respectively, potentially upregulating proteins involved in these signaling cascades, such as 1810055G02Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate various target proteins. If 1810055G02Rik is a substrate of PKC, or part of a PKC-dependent pathway, its activity could be enhanced through this mechanism. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit certain protein kinases. This inhibition can lead to an increase in the activity of proteins that are regulated by these kinases through a negative feedback loop, potentially including 1810055G02Rik. | ||||||
Sodium Fluoride | 7681-49-4 | sc-24988A sc-24988 sc-24988B | 5 g 100 g 500 g | $39.00 $45.00 $98.00 | 26 | |
NaF is an activator of various phosphatases by mimicking phosphate groups. If 1810055G02Rik is regulated by phosphorylation, NaF could enhance its activity by affecting its phosphorylation state. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P acts on its receptors to activate intracellular signaling pathways including PI3K/AKT, potentially leading to the activation of downstream proteins that could be associated with 1810055G02Rik. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases could result in enhanced phosphorylation and activation of target proteins, possibly including 1810055G02Rik. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a potent activator of the JNK/SAPK signaling pathway. If 1810055G02Rik is a component or modulator within this pathway, anisomycin could enhance its activity by this stimulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. By blocking this kinase, it can modulate signaling pathways, potentially leading to the activation of proteins that function in parallel to the PI3K pathway, including 1810055G02Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin increases intracellular calcium levels by inhibiting the Ca2+-ATPase of the endoplasmic reticulum. If 1810055G02Rik is regulated by calcium-dependent signaling, this could lead to its activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as an ionophore, facilitating the transport of Ca2+ across cellular membranes. Enhanced intracellular calcium can activate numerous calcium-dependent proteins and pathways, which may include 1810055G02Rik. | ||||||